IDEXX Laboratories, Inc. (IDXX) 10-Year Financial Performance & Capital Metrics

IDXX • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

AboutIDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.Show more

Revenue $3.9B +6.5%
EBITDA $1.26B +3.8%
Net Income $888M +5.1%
EPS (Diluted) 10.67 +6.1%
Gross Margin 61.04% +2.0%
EBITDA Margin 32.28% -2.5%
Operating Margin 28.95% -3.4%
Net Margin 22.78% -1.3%
ROE 57.66% -28.6%
ROIC 38.54% -4.8%
Debt/Equity 0.62 -14.0%
Interest Coverage 36.16 +37.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 81.0%
✓Strong 5Y profit CAGR of 15.7%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 20.5% free cash flow margin
✓Strong 5Y sales CAGR of 10.1%
✓Healthy 5Y average net margin of 22.1%

✗Weaknesses

✗Expensive at 37.2x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y10.12%

5Y10.12%

3Y6.62%

TTM8.39%

Profit (Net Income) CAGR

10Y17.18%

5Y15.73%

3Y6.03%

TTM18.61%

EPS CAGR

10Y19.54%

5Y16.89%

3Y7.45%

TTM21.6%

ROCE

10Y Avg56.53%

5Y Avg53.6%

3Y Avg54.56%

Latest49.77%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.6B	1.78B	1.97B	2.21B	2.41B	2.71B	3.22B	3.37B	3.66B	3.9B
Revenue Growth %	0.08%	0.11%	0.11%	0.12%	0.09%	0.12%	0.19%	0.05%	0.09%	0.06%
Cost of Goods Sold+	711.62M	799.99M	871.68M	971.7M	1.04B	1.14B	1.33B	1.36B	1.47B	1.52B
COGS % of Revenue	0.44%	0.45%	0.44%	0.44%	0.43%	0.42%	0.41%	0.4%	0.4%	0.39%
Gross Profit+	890.27M	975.44M	1.1B	1.24B	1.37B	1.57B	1.89B	2B	2.19B	2.38B
Gross Margin %	0.56%	0.55%	0.56%	0.56%	0.57%	0.58%	0.59%	0.6%	0.6%	0.61%
Gross Profit Growth %	0.09%	0.1%	0.13%	0.13%	0.1%	0.15%	0.2%	0.06%	0.09%	0.09%
Operating Expenses+	582.15M	625.2M	684.35M	750.21M	812.7M	876.52M	957.4M	1.11B	1.09B	1.25B
OpEx % of Revenue	0.36%	0.35%	0.35%	0.34%	0.34%	0.32%	0.3%	0.33%	0.3%	0.32%
Selling, General & Admin	482.46M	524.08M	575.17M	632.34M	679.51M	735.27M	796.39M	850.75M	901.89M	1.03B
SG&A % of Revenue	0.3%	0.3%	0.29%	0.29%	0.28%	0.27%	0.25%	0.25%	0.25%	0.26%
Research & Development	99.68M	101.12M	109.18M	117.86M	133.19M	141.25M	161.01M	254.82M	190.95M	219.79M
R&D % of Revenue	0.06%	0.06%	0.06%	0.05%	0.06%	0.05%	0.05%	0.08%	0.05%	0.06%
Other Operating Expenses	0	0	0	0	0	0	1.46M	2.2M	0	0
Operating Income+	299.91M	350.24M	413.03M	491.33M	552.85M	694.52M	932.03M	898.76M	1.1B	1.13B
Operating Margin %	0.19%	0.2%	0.21%	0.22%	0.23%	0.26%	0.29%	0.27%	0.3%	0.29%
Operating Income Growth %	0.15%	0.17%	0.18%	0.19%	0.13%	0.26%	0.34%	-0.04%	0.22%	0.03%
EBITDA+	368.87M	428.46M	496.17M	574.51M	640.86M	790.52M	1.04B	1.01B	1.21B	1.26B
EBITDA Margin %	0.23%	0.24%	0.25%	0.26%	0.27%	0.29%	0.32%	0.3%	0.33%	0.32%
EBITDA Growth %	0.16%	0.16%	0.16%	0.16%	0.12%	0.23%	0.31%	-0.03%	0.2%	0.04%
D&A (Non-Cash Add-back)	68.96M	78.22M	83.14M	83.18M	88.01M	96M	104.6M	111.9M	114.91M	129.94M
EBIT	302.38M	353.89M	418.28M	492.49M	553.27M	695.11M	932.46M	899.83M	1.1B	1.14B
Net Interest Income+	-26.77M	-28.39M	-31.97M	-33.59M	-30.63M	-32.54M	-29.37M	-38.79M	-35.95M	-18.51M
Interest Income	2.47M	3.66M	5.25M	1.15M	427K	586K	434K	1.06M	5.63M	12.7M
Interest Expense	29.24M	32.05M	37.23M	34.74M	31.05M	33.13M	29.81M	39.86M	41.58M	31.2M
Other Income/Expense	-26.77M	-28.39M	-31.97M	-33.59M	-30.63M	-32.54M	-29.37M	-38.79M	-35.95M	-18.51M
Pretax Income+	273.14M	321.85M	381.06M	457.74M	522.22M	661.99M	902.65M	859.97M	1.06B	1.11B
Pretax Margin %	0.17%	0.18%	0.19%	0.21%	0.22%	0.24%	0.28%	0.26%	0.29%	0.28%
Income Tax+	81.01M	99.79M	117.79M	80.69M	94.43M	79.85M	157.81M	180.88M	216.13M	221.96M
Effective Tax Rate %	0.7%	0.69%	0.69%	0.82%	0.82%	0.88%	0.83%	0.79%	0.8%	0.8%
Net Income+	192.08M	222.04M	263.14M	377.03M	427.72M	581.78M	744.85M	679.09M	845.04M	887.87M
Net Margin %	0.12%	0.13%	0.13%	0.17%	0.18%	0.21%	0.23%	0.2%	0.23%	0.23%
Net Income Growth %	0.06%	0.16%	0.19%	0.43%	0.13%	0.36%	0.28%	-0.09%	0.24%	0.05%
Net Income (Continuing)	192.13M	222.05M	263.27M	377.05M	427.79M	582.13M	744.84M	679.09M	845.04M	887.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	130K	139K	264K	280K	352K	707K	0	0	0	0
EPS (Diluted)+	2.05	2.44	2.94	4.26	4.89	6.71	8.60	8.03	10.06	10.67
EPS Growth %	0.15%	0.19%	0.2%	0.45%	0.15%	0.37%	0.28%	-0.07%	0.25%	0.06%
EPS (Basic)	2.07	2.47	3.00	4.34	4.97	6.82	8.74	8.12	10.17	10.77
Diluted Shares Outstanding	93.65M	90.88M	89.57M	88.47M	87.54M	86.72M	86.57M	84.6M	83.98M	83.25M
Basic Shares Outstanding	92.6M	89.73M	87.77M	86.86M	86.11M	85.34M	85.2M	83.62M	83.07M	82.47M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	821.63M	845.58M	971.99M	654.17M	679.64M	1.06B	955.65M	1.1B	1.5B	1.4B
Cash & Short-Term Investments	342.58M	391.85M	471.93M	123.79M	90.33M	383.93M	144.45M	112.55M	453.93M	288.27M
Cash Only	128.99M	154.9M	187.68M	123.79M	90.33M	383.93M	144.45M	112.55M	453.93M	288.27M
Short-Term Investments	213.59M	236.95M	284.25M	0	0	0	0	0	0	0
Accounts Receivable	200.11M	232.17M	270.07M	258.52M	307.49M	374.74M	425.58M	490.9M	529.53M	561.32M
Days Sales Outstanding	45.6	47.73	50.06	42.63	46.63	50.53	48.31	53.21	52.79	52.57
Inventory	188.83M	158.03M	164.32M	173.3M	195.02M	209.87M	269.03M	367.82M	380.28M	381.88M
Days Inventory Outstanding	96.85	72.1	68.81	65.1	68.35	67.46	74.06	98.5	94.36	91.79
Other Current Assets	101.9M	91.21M	101.14M	54.14M	54.81M	59.64M	74.59M	88.46M	83.14M	109.81M
Total Non-Current Assets+	653.36M	685.12M	741.43M	883.18M	1.15B	1.23B	1.48B	1.65B	1.76B	1.89B
Property, Plant & Equipment	333.03M	357.42M	379.1M	437.27M	614.45M	646.34M	692.77M	768.09M	817.68M	829.25M
Fixed Asset Turnover	4.81x	4.97x	5.19x	5.06x	3.92x	4.19x	4.64x	4.38x	4.48x	4.70x
Goodwill	178.93M	178.23M	199.87M	214.49M	239.72M	243.35M	359.35M	361.8M	365.96M	405.1M
Intangible Assets	55.91M	46.16M	43.85M	41.83M	58.47M	52.54M	99.03M	97.67M	84.5M	111.68M
Long-Term Investments	12.16M	10.98M	9.95M	10.89M	13.66M	12.06M	18.6M	55.5M	56.19M	57.72M
Other Non-Current Assets	73.33M	86.63M	100.97M	170.22M	218.44M	245.98M	287.02M	307.01M	332.98M	364.17M
Total Assets+	1.47B	1.53B	1.71B	1.54B	1.83B	2.29B	2.44B	2.75B	3.26B	3.29B
Asset Turnover	1.09x	1.16x	1.15x	1.44x	1.31x	1.18x	1.32x	1.23x	1.12x	1.18x
Asset Growth %	0.07%	0.04%	0.12%	-0.1%	0.19%	0.25%	0.06%	0.13%	0.19%	0.01%
Total Current Liabilities+	856.76M	934.57M	1B	770.44M	725.34M	582.76M	763.58M	1.24B	951.55M	1.07B
Accounts Payable	52.65M	60.06M	66.97M	69.53M	72.17M	74.56M	116.14M	110.22M	110.64M	114.21M
Days Payables Outstanding	27	27.4	28.04	26.12	25.3	23.96	31.97	29.52	27.45	27.45
Short-Term Debt	573M	611M	655M	398.94M	288.76M	49.99M	148.5M	653.98M	325M	417.79M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	77.03M	91.11M	102.94M	109.49M	127.17M	167.65M	182.93M	142.99M	174.38M	174.58M
Current Ratio	0.96x	0.90x	0.97x	0.85x	0.94x	1.82x	1.25x	0.89x	1.57x	1.31x
Quick Ratio	0.74x	0.74x	0.80x	0.62x	0.67x	1.46x	0.90x	0.59x	1.17x	0.95x
Cash Conversion Cycle	115.45	92.43	90.83	81.61	89.69	94.03	90.4	122.2	119.7	116.9
Total Non-Current Liabilities+	702.23M	704.35M	762.69M	776.14M	929.31M	1.08B	983.63M	902.23M	823.85M	630.21M
Long-Term Debt	597.09M	593.11M	606.08M	601.35M	698.91M	858.49M	775.21M	694.39M	622.88M	449.79M
Capital Lease Obligations	0	0	0	0	67.47M	77.04M	87.38M	101.24M	99.67M	97.84M
Deferred Tax Liabilities	49.39M	39.29M	25.35M	29.27M	33.02M	11.71M	8.94M	8.15M	7.24M	11.31M
Other Non-Current Liabilities	28.7M	38.94M	95.72M	84.83M	81.16M	85.6M	70.94M	67.59M	65.53M	44.34M
Total Liabilities	1.56B	1.64B	1.77B	1.55B	1.65B	1.66B	1.75B	2.14B	1.78B	1.7B
Total Debt+	1.17B	1.2B	1.26B	1B	1.07B	1B	1.03B	1.47B	1.07B	986.95M
Net Debt	1.04B	1.05B	1.07B	876.49M	980.1M	619.32M	886.55M	1.36B	613.42M	698.68M
Debt / Equity	-	-	-	-	6.02x	1.59x	1.49x	2.41x	0.72x	0.62x
Debt / EBITDA	3.17x	2.81x	2.54x	1.74x	1.67x	1.27x	0.99x	1.45x	0.88x	0.78x
Net Debt / EBITDA	2.82x	2.45x	2.16x	1.53x	1.53x	0.78x	0.86x	1.34x	0.51x	0.56x
Interest Coverage	10.26x	10.93x	11.10x	14.14x	17.80x	20.97x	31.27x	22.55x	26.39x	36.16x
Total Equity+	-84M	-108.21M	-53.84M	-9.23M	177.82M	632.79M	689.99M	608.74M	1.48B	1.6B
Equity Growth %	-1.71%	-0.29%	0.5%	0.83%	20.26%	2.56%	0.09%	-0.12%	1.44%	0.07%
Book Value per Share	-0.90	-1.19	-0.60	-0.10	2.03	7.30	7.97	7.20	17.68	19.16
Total Shareholders' Equity	-84.13M	-108.35M	-54.11M	-9.51M	177.47M	632.09M	689.99M	608.74M	1.48B	1.6B
Common Stock	10.26M	10.33M	10.43M	10.51M	10.57M	10.65M	10.69M	10.72M	10.75M	10.78M
Retained Earnings	318.36M	540.4M	803.54M	1.17B	1.6B	2.18B	2.92B	3.6B	4.44B	5.33B
Treasury Stock	-1.32B	-1.63B	-1.91B	-2.29B	-2.6B	-2.8B	-3.57B	-4.39B	-4.47B	-5.33B
Accumulated OCI	-42.27M	-43.05M	-36.47M	-41.79M	-46.18M	-53.62M	-53.48M	-77.8M	-71.21M	-93.64M
Minority Interest	130K	139K	264K	280K	352K	707K	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	216.36M	334.57M	373.28M	400.08M	459.16M	648.06M	755.55M	542.98M	906.51M	929M
Operating CF Margin %	0.14%	0.19%	0.19%	0.18%	0.19%	0.24%	0.23%	0.16%	0.25%	0.24%
Operating CF Growth %	-0.08%	0.55%	0.12%	0.07%	0.15%	0.41%	0.17%	-0.28%	0.67%	0.02%
Net Income	192.13M	222.05M	263.27M	377.05M	427.79M	582.13M	744.84M	679.09M	845.04M	887.87M
Depreciation & Amortization	68.96M	78.22M	83.14M	83.18M	88.01M	96M	104.6M	111.9M	114.91M	129.94M
Stock-Based Compensation	19.88M	19.89M	23.52M	25.16M	39.28M	30.95M	37.76M	49.77M	59.74M	60.3M
Deferred Taxes	5.14M	20.88M	-7.92M	1.21M	6.16M	-38.08M	-3.38M	-35.06M	-48.31M	-24.19M
Other Non-Cash Items	57K	-9.47M	2.89M	5.13M	2.88M	8.83M	9.25M	10.82M	7.56M	8.34M
Working Capital Changes	-69.81M	3M	8.38M	-91.64M	-104.97M	-31.76M	-137.52M	-273.53M	-72.43M	-133.24M
Change in Receivables	-50.14M	-22.55M	-24.92M	-18.4M	-22.47M	-60.72M	-33.14M	-41.4M	-53.87M	-28.28M
Change in Inventory	-34.97M	7.65M	-19.06M	-25.62M	-37.31M	-18.89M	-52.92M	-121.73M	-28.65M	-28M
Change in Payables	-2.47M	2.12M	1.39M	-166K	1.96M	981K	11.23M	3.47M	-557K	8.09M
Cash from Investing+	-308.41M	-90.79M	-138.69M	138.6M	-205.53M	-109.38M	-292.97M	-195.35M	-125.25M	-207.06M
Capital Expenditures	-82.92M	-64.79M	-76.7M	-122.94M	-155.22M	-107.63M	-119.55M	-148.84M	-133.63M	-120.92M
CapEx % of Revenue	0.05%	0.04%	0.04%	0.06%	0.06%	0.04%	0.04%	0.04%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	-46.51M	8.38M	-10M
Cash from Financing+	-95.55M	-217.82M	-208.02M	-597.8M	-286.41M	-248.42M	-697.41M	-370.94M	-442M	-878.07M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	11.31M	9.97M	0	-10.64M	-10.43M	-22.28M	-20.7M	-17.04M	-13.11M	-10.53M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	133.44M	269.78M	296.57M	277.15M	303.93M	540.44M	636M	394.15M	772.88M	798.08M
FCF Margin %	0.08%	0.15%	0.15%	0.13%	0.13%	0.2%	0.2%	0.12%	0.21%	0.2%
FCF Growth %	-0.24%	1.02%	0.1%	-0.07%	0.1%	0.78%	0.18%	-0.38%	0.96%	0.03%
FCF per Share	1.42	2.97	3.31	3.13	3.47	6.23	7.35	4.66	9.20	9.59
FCF Conversion (FCF/Net Income)	1.13x	1.51x	1.42x	1.06x	1.07x	1.11x	1.01x	0.80x	1.07x	1.05x
Interest Paid	27.19M	0	0	0	0	0	0	0	0	0
Taxes Paid	54.88M	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	1143.53%	-	-	-	507.4%	143.54%	112.62%	104.58%	80.74%	57.66%
Return on Invested Capital (ROIC)	27.25%	27.68%	31.6%	39.06%	40.95%	43.23%	49.42%	38.05%	40.49%	38.54%
Gross Margin	55.58%	54.94%	55.73%	56.1%	56.73%	58.04%	58.76%	59.52%	59.82%	61.04%
Net Margin	11.99%	12.51%	13.36%	17.04%	17.77%	21.49%	23.17%	20.17%	23.08%	22.78%
Debt / Equity	-	-	-	-	6.02x	1.59x	1.49x	2.41x	0.72x	0.62x
Interest Coverage	10.26x	10.93x	11.10x	14.14x	17.80x	20.97x	31.27x	22.55x	26.39x	36.16x
FCF Conversion	1.13x	1.51x	1.42x	1.06x	1.07x	1.11x	1.01x	0.80x	1.07x	1.05x
Revenue Growth	7.81%	10.83%	10.91%	12.4%	8.75%	12.45%	18.79%	4.73%	8.72%	6.46%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	2.09B	2.25B
Product Growth	-	-	-	-	-	-	-	-	-	7.57%
Service	-	-	-	-	-	-	-	-	1.57B	1.65B
Service Growth	-	-	-	-	-	-	-	-	-	4.98%
Up Front Customer Loyalty Programs And Volume Commitment Programs	-	-	-	1.3B	1.9B	2.2B	2.9B	3.2B	-	-
Up Front Customer Loyalty Programs And Volume Commitment Programs Growth	-	-	-	-	46.15%	15.79%	31.82%	10.34%	-	-
Reagent Rental Programs	-	-	-	49.6M	31.6M	24.8M	38.3M	42.8M	-	-
Reagent Rental Programs Growth	-	-	-	-	-36.29%	-21.52%	54.44%	11.75%	-	-
Extended Warranties And Post Contract Support	-	-	-	27.7M	24.4M	22M	23.1M	21.3M	-	-
Extended Warranties And Post Contract Support Growth	-	-	-	-	-11.91%	-9.84%	5.00%	-7.79%	-	-
Instrument Rebate Programs	-	-	-	18.2M	18.1M	16.3M	14.3M	12M	-	-
Instrument Rebate Programs Growth	-	-	-	-	-0.55%	-9.94%	-12.27%	-16.08%	-	-
Rapid Assay Products	-	-	205.31M	-	-	-	-	-	-	-
Rapid Assay Products Growth	-	-	-	-	-	-	-	-	-	-
Cag	1.15B	1.28B	-	-	-	-	-	-	-	-
Cag Growth	-	11.75%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	1.36B	1.5B	1.69B	2B	2.18B	2.39B	2.53B
UNITED STATES Growth	-	-	-	-	10.13%	13.09%	18.00%	9.38%	9.55%	5.93%
EMEA	-	-	-	472.07M	498.44M	562.76M	681.95M	647.03M	716.18M	806.73M
EMEA Growth	-	-	-	-	5.59%	12.91%	21.18%	-5.12%	10.69%	12.64%
Asia Pacific	-	-	-	294.96M	317.94M	361.61M	420.9M	319.55M	423.42M	321.02M
Asia Pacific Growth	-	-	-	-	7.79%	13.73%	16.40%	-24.08%	32.50%	-24.18%
CANADA	-	-	-	94.21M	99.55M	107.4M	139.73M	142.74M	150.11M	152.88M
CANADA Growth	-	-	-	-	5.67%	7.88%	30.10%	2.16%	5.16%	1.85%
Latin America	-	-	-	50.97M	56.52M	51.86M	66.62M	75.03M	83.92M	83.69M
Latin America Growth	-	-	-	-	10.88%	-8.23%	28.46%	12.63%	11.85%	-0.28%

Frequently Asked Questions

Valuation & Price

IDEXX Laboratories, Inc. (IDXX) has a price-to-earnings (P/E) ratio of 66.7x. This suggests investors expect higher future growth.

Growth & Financials

IDEXX Laboratories, Inc. (IDXX) reported $4.17B in revenue for fiscal year 2024. This represents a 242% increase from $1.22B in 2011.

IDEXX Laboratories, Inc. (IDXX) grew revenue by 6.5% over the past year. This is steady growth.

Yes, IDEXX Laboratories, Inc. (IDXX) is profitable, generating $1.03B in net income for fiscal year 2024 (22.8% net margin).

Dividend & Returns

IDEXX Laboratories, Inc. (IDXX) has a return on equity (ROE) of 57.7%. This is excellent, indicating efficient use of shareholder capital.

IDEXX Laboratories, Inc. (IDXX) generated $953.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...